This article is more than 5 years old. Information may no longer be current.
Enrollment begins for study of transcatheter tricuspid valve repair system
Click Here to Manage Email Alerts
Abbott announced the first patient has been enrolled in a study of a minimally invasive clip-based repair system for treating people with moderate or severe tricuspid regurgitation, according to a press release.
The study, TRILUMINATE, will evaluate the clip-based technology in about 75 patients in a prospective, single-arm, multicenter study in the U.S. and Europe.
The researchers will assess for echocardiographic tricuspid regurgitation reduction of at least one grade at 30 days post-procedure and major adverse events at 6 months.
“Current pharmacological and surgical treatment options are not meeting the needs of people living with tricuspid regurgitation,” Georg Nickenig, MD, PhD, professor and chief of cardiology at University Hospital, Bonn, Germany, said in the release. “Abbott’s MitraClip has shown positive results for mitral regurgitation, and we hope this study shows that a similar clip-based technology may effectively treat people with tricuspid regurgitation.”
The first patient was enrolled by Paul Sorajja, MD, cardiologist at Minneapolis Heart Institute and Abbott Northwestern Hospital.